Karl L Banta
Overview
Explore the profile of Karl L Banta including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
566
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nutsch K, Banta K, Wu T, Tran C, Mittman S, Duong E, et al.
Nat Cancer
. 2025 Jan;
6(2):405.
PMID: 39825000
No abstract available.
2.
Nutsch K, Banta K, Wu T, Tran C, Mittman S, Duong E, et al.
Nat Cancer
. 2024 Dec;
5(12):1834-1851.
PMID: 39681653
Blockade of immune checkpoints PD-1 and TIGIT has demonstrated activity in mouse tumor models and human patients with cancer. Although these coinhibitory receptors can restrict signaling in CD8 T cells...
3.
Guan X, Hu R, Choi Y, Srivats S, Nabet B, Silva J, et al.
Nature
. 2024 Aug;
633(8030):E1.
PMID: 39164390
No abstract available.
4.
Guan X, Hu R, Choi Y, Srivats S, Nabet B, Silva J, et al.
Nature
. 2024 May;
630(8016):E9.
PMID: 38816613
No abstract available.
5.
Guan X, Hu R, Choi Y, Srivats S, Nabet B, Silva J, et al.
Nature
. 2024 Mar;
627(8005):E11.
PMID: 38480897
No abstract available.
6.
Guan X, Hu R, Choi Y, Srivats S, Nabet B, Silva J, et al.
Nature
. 2024 Feb;
627(8004):646-655.
PMID: 38418879
Tiragolumab, an anti-TIGIT antibody with an active IgG1κ Fc, demonstrated improved outcomes in the phase 2 CITYSCAPE trial (ClinicalTrials.gov: NCT03563716 ) when combined with atezolizumab (anti-PD-L1) versus atezolizumab alone. However,...
7.
Banta K, Xu X, Chitre A, Au-Yeung A, Takahashi C, OGorman W, et al.
Immunity
. 2022 Mar;
55(3):512-526.e9.
PMID: 35263569
Dual blockade of the PD-1 and TIGIT coinhibitory receptors on T cells shows promising early results in cancer patients. Here, we studied the mechanisms whereby PD-1 and/or TIGIT blockade modulate...
8.
Wu T, Madireddi S, de Almeida P, Banchereau R, Chen Y, Chitre A, et al.
Nature
. 2020 Feb;
579(7798):274-278.
PMID: 32103181
Despite the resounding clinical success in cancer treatment of antibodies that block the interaction of PD1 with its ligand PDL1, the mechanisms involved remain unknown. A major limitation to understanding...
9.
Chiang E, de Almeida P, de Almeida Nagata D, Bowles K, Du X, Chitre A, et al.
Eur J Immunol
. 2020 Feb;
50(6):891-902.
PMID: 32043568
CD96 is a member of the poliovirus receptor (PVR, CD155)-nectin family that includes T cell Ig and ITIM domain (TIGIT) and CD226. While CD96, TIGIT, and CD226 have important roles...
10.
Banta K, Wang X, Das P, Winoto A
J Biol Chem
. 2018 Feb;
293(13):4724-4734.
PMID: 29414782
Apoptosis is mediated through the extrinsic or intrinsic pathway. Key regulators of the intrinsic apoptotic pathway are the family of B cell lymphoma 2 (Bcl-2) proteins. The activity of the...